Dr. Issa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
403 Haddon Ave
Philadelphia, PA 19140
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1990 - 1994
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1987 - 1990
American University of Beirut Faculty of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 2011 - 2022
TX State Medical License 2004 - 2011
MD State Medical License 1989 - 2004
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2003
Clinical Trials
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2003 Jan 01
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders Start of enrollment: 2005 May 01
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Association between gut microbiota and CpG island methylator phenotype in colorectal cancer.Pyoung Hwa Park, Kelsey Keith, Gennaro Calendo, Jaroslav Jelinek, Jozef Madzo
Gut Microbes. 2024-06-11 - Genome-wide screening and functional validation of methylation barriers near promoters.Jingmin Shu, Jaroslav Jelinek, Hai Chen, Yan Zhang, Taichun Qin
Nucleic Acids Research. 2024-05-22 - 4 citationsTissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD.Ying Wang, Shan He, Gennaro Calendo, Tien Bui, Yuanyuan Tian
Blood. 2024-01-11
Abstracts/Posters
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients wit...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinica...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Coriell Institute for Medical Research Scientist Receives Grant to Find Drivers of Breast CancerDecember 5th, 2019- Predictors of Response to Guadecitabine Found in Relapsed/Refractory AML PatientsSeptember 12th, 2019
- Coriell Institute for Medical Research Now a Collaborator in Prestigious Stand up to Cancer GrantJuly 19th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
